SALT LAKE CITY--(BUSINESS WIRE)--“Rich McKeown brings a deep understanding of the healthcare industry as the chief executive of one of the nation’s most respected healthcare consulting firms,” said ProLung President and CEO Steven Eror when he announced Leavitt Partners CEO Rich McKeown as the newest member of the Company’s board of directors.
“As Chief of Staff to US Department of Health and Human Services Secretary Mike Leavitt during the George W. Bush Administration, Mr. McKeown oversaw the daily operations of the Secretary, which included managing 27 federal agencies and overseeing the largest federal departmental budget. His insights and expertise will be valuable as we enter into an exciting phase of our Company’s growth and development with the launch of distribution and sales in Europe and our continued efforts to obtain the approvals required to market in the US.”
ProLung developed a patented, highly innovative, non-invasive, non-radiating Electro Pulmonary Nodule Scan, or EPN Scan, as an aid in the diagnosis of lung cancer, the deadliest form of cancer. In Europe, the EPN Scan is marketed as Freshmedx. In the US, the Company plans to market the EPN Scan, subject to FDA approval, as ProLung.
In well-controlled clinical testing published in the Journal of Thoracic Oncology in 2012, the EPN Scan correctly categorized patients with malignant lung lesions with a 90% accuracy rate.
“At Leavitt Partners, we collaborate with clients and through our Health Intelligence Partners forum provide a window into the future of healthcare,” said McKeown. “The ProLung EPN device and Scan is the type of pioneering medical technology that we need available in the market to save lives.”
About ProLung: Known as ProLung in the US and Freshmedx in Europe, the Salt Lake City-based medical technology company is dedicated to lung health and improving outcomes for lung cancer patients. Its management has a collective 40 years of relevant healthcare and biotechnology experience and its researchers feature highly respected global leaders in lung cancer detection. The technology described in this release is currently investigational in the US and neither the EPN Scan nor related statements have been approved by the US FDA. For more information, please go to www.prolungdx.com in the US or www.freshmedx.com in Europe.
This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the Company’s actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that the Company’s EPN Scan will not receive required marketing approval from the FDA for marketing in the United States and that, even if such approval is received, the EPN Scan will not prove reliable in identifying likely cancerous masses in practice to the same extent as in laboratory tests. In addition, other risks are identified in the company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC. Such forward-looking statements speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.